CoChat

Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study)

Open access
Giovanazzi, Alexia, Gios, Lorenzo, Gentilini, Maria Adalgisa, Mastellaro, Marina, Bartolotta, Patrizia, Nicolussi Giacomaz, Lucrezia, Eccher, Claudio, Inchiostro, Sandro · 2025 · Frontiers in Clinical Diabetes and Healthcare

The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index; 19 of the 22 sources its claims cite were checked for support.

Abstract

Background: The use of technologies in the health field has progressively increased. Within the context of a broader project funded by the Italian Ministry of Health (TELEMECHRON study), a randomised controlled trial (RCT) has been conducted in the Autonomous Province of Trento on type 2 diabetes individuals with an untargeted glycated haemoglobin (HbA1c) level. Methods: The overall aim was to evaluate the impact of the “TreC Diabete” digital platform, including a smartphone application (app) and a dashboard. This open-label, parallel-group, 1:1 allocation ratio RCT in which the intervention group used the app for data entry, symptoms questionnaire, communication with healthcare staff and medication recording, while the control group received standard care. The primary endpoint was change in HbA1c levels at 12 months between groups. Results: Between December 2022 and August 2023, 103 participants were enrolled (51 intervention; 52 control), with a median age of 67 years old, time from diabetes diagnosis to enrolment 13 years, and 72% male. At 12 months, the median change in HbA1c levels did not differ significantly between groups. Regarding app usage, data entries decreased significantly from the first quarter to the second quarter but subsequently stabilised (p = 0.001). System usability (from 42 responders in the intervention group) had a median score of 95 (range: 0–100), indicating a high level of satisfaction with the platform. Discussion: The study faced several challenges, including platform technical issues, service interruption, data entry anomalies and difficulties in participant recruitment. Study generalisability may be limited by the sample’s demographics, as the trial predominantly included younger male individuals with a specific HbA1c level. Conclusion: The study highlighted key factors for future implementations, including understanding technology benefits, addressing adoption barriers, and providing education and support to both patients and healthcare providers.

Overview

CoChat Summary

TL;DR

In this open-label RCT, the “TreC Diabete” digital platform did not improve 12-month HbA1c change compared with standard care in adults with Type 2 diabetes and non-target HbA1c. Both groups improved glycaemia, while app usage declined early and then stabilised, and usability was rated highly by responders.

Key findings

  • Among 103 participants (51 intervention; 52 control), median HbA1c change at 12 months was -6 mmol/mol (IQR -12 to -4) in the intervention group vs -7 mmol/mol (IQR -14 to 0) in the control group, with no significant between-group difference (p > 0.9); both groups decreased significantly from baseline (p < 0.001).
  • Glycaemic target achievement (HbA1c < 53 mmol/mol) was 51% in the intervention group vs 42% in the control group (p = 0.4), and secondary clinical outcomes such as weight, LDL cholesterol, non-HDL cholesterol, and blood pressure showed no significant between-group differences.
  • App data entries decreased significantly from the first to second quarter and then stabilised (median T1: 150, IQR 52–444; T2: 84, IQR 37–423; T3: 68, IQR 19–449; T4: 66, IQR 9–413; p = 0.001).
  • System usability, assessed in 42 intervention-group responders, had a median SUS score of 95 (IQR 78–99), indicating high satisfaction.

Methods

  • Open-label, parallel-group, superiority RCT with 1:1 allocation; participants were adults aged 18–85 with HbA1c between 53 and 108 mmol/mol, recruited from outpatient diabetes centres in the Autonomous Province of Trento between December 2022 and August 2023.
  • The intervention group used the “TreC Diabete” app for data entry, symptoms questionnaire, communication with healthcare staff, and medication recording, while the control group received standard care.
  • The primary endpoint was change in HbA1c at 12 months; analysis followed intention-to-treat with multiple imputation by chained equations when feasible, plus sensitivity, per-protocol, and as-treated analyses.

Limitations

  • The paper states technical and operational problems including outdated WebView/app startup issues, complex profile creation, two service interruptions (2 and 12 days), data entry anomalies, recruitment difficulties, smaller-than-planned sample (103 of 120), missing data, low event numbers for secondary outcomes, possible dilution of intervention effect from control-group interactions, and telephone data collection more frequent than planned.
  • The paper states generalisability limits: the sample was slightly younger (median 67 vs 70 years in the provincial T2DM population), predominantly male (71.8% vs 56.4%), and restricted to participants with HbA1c 53–108 mmol/mol, while over 50% of the provincial diabetic population had HbA1c below 53 mmol/mol.
  • Evident from the text: the open-label design meant participants, clinicians, and data collectors were aware of allocation, and the app-engagement threshold of ≥6 recorded entries per month was arbitrarily defined.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fcdhc.2025.1589548

Cites

33 of 34 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 “TreC Diabete” app user interface and dashboard interface.
Figure 1 “TreC Diabete” app user interface and dashboard interface.CC BY · PubMed Central
Figure 2 Adapted Consolidated Standard of Reporting Trials flow chart – from eligibility assessment to analysis (28).
Figure 2 Adapted Consolidated Standard of Reporting Trials flow chart – from eligibility assessment to analysis (28).CC BY · PubMed Central
Figure 3 Median frequency of data entry every 4 months over12 months by the intervention group.
Figure 3 Median frequency of data entry every 4 months over12 months by the intervention group.CC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 0 Not valid · 1 Not checked · 101 Own results and interpretations

35 more claims

Create a free account to see all 116 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 45
  • Probably not a substantial claim. 47

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 6 · the rest aren’t loaded

1 more finding

Create a free account to see every finding of this check.

See all findings — free account

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 34 references

Research works printed but not linked: 6

  1. 2016, Global report on diabetes
  2. 2024, R: A language and environment for statistical computing
  3. 2018, The johns hopkins ACG
  4. 2019, Qualità di cura in base al genere nel DM2
  5. 2014, World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, J. Am. Coll. Dent., 81, 10.1111/1753-0407.13346 · DOI · Paper page
  6. 2015, Guideline, ICH Harmonised. “Integrated addendum to ICH E6 (R1): guideline for good clinical practice E6 (R2), Curr. Step, 2, 1, 10.7759/cureus.51791 · doi:10.7759/cureus.51791 · Paper page

Metadata

Authors
Giovanazzi, A., Gios, L., Gentilini, M. A., Mastellaro, M., Bartolotta, P., Nicolussi Giacomaz, L., Eccher, C., & Inchiostro, S.
Affiliations
  • Provincia Autonoma di Trento (IT)
  • Fondazione Bruno Kessler (IT)
Corresponding author
Inchiostro, Sandro
Venue
Frontiers in Clinical Diabetes and Healthcare
Published
2025-06-10
Volume
6
Pages
1589548-1589548
ISSN
2673-6616 (ISSN-L)
OpenAlex
W4411187109
Cited by
2
References
33
Citations by year
2026: 1 · 2025: 1
FWCI
2.52
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Clinical Diabetes and Healthcare (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Fondazione Bruno Kessler
Topics
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, digital health, mobile application, HbA1c, diabetes self-management, patient-reported outcomes, system usability, technology adoption barriers, remote patient monitoring

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study). https://app.cochat.ai/papers/10.3389/fcdhc.2025.1589548
The paper
Giovanazzi, A., Gios, L., Gentilini, M. A., Mastellaro, M., Bartolotta, P., Nicolussi Giacomaz, L., Eccher, C., & Inchiostro, S. (2025). Impact of digital health on Type 2 diabetes management: a randomised controlled trial of the ‘TreC Diabete’ platform (TELEMECHRON Study). Frontiers in Clinical Diabetes and Healthcare. https://doi.org/10.3389/fcdhc.2025.1589548

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.